Mark Swanson

Executive Vice President, Head-Research & Strategic Development at Gel Med Sciences, Inc.

Mark Swanson

Mark Swanson

Executive Vice President, Head-Research & Strategic Development at Gel Med Sciences, Inc.

Biography

Mark Swanson is Executive Vice President at Gel Med Sciences, Inc. He previously occupied the position of Senior Scientist at Sandoz Pharmaceuticals Corp. and Vice President-Transgenic Sciences at DNX Transgenic Sciences. He received a doctorate from the University of Connecticut.

Overview
RelSci Relationships

312

Contact Data
Trying to get in touch with Mark Swanson? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Mark Swanson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Vice Chairman at Jefferson Health System, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Gel Med Sciences, Inc.

Relationship likelihood: Strong

Head-Clinical Development at Gel Med Sciences, Inc.

Relationship likelihood: Strong

Former Chairman & Acting Chief Executive Officer at North Park University

Relationship likelihood: Average

Professional at Gel Med Sciences, Inc.

Relationship likelihood: Average

Partner at Novitas Capital III LP

Relationship likelihood: Average

Executive Director, Investment Office at The Pennsylvania State University

Relationship likelihood: Average

President at The Pennsylvania State University

Relationship likelihood: Average

Executive Director, Student Disability Resources at The Pennsylvania State University

Relationship likelihood: Average

Owner at The Pennsylvania State University

Relationship likelihood: Average

Paths to Mark Swanson
Potential Connections via
Relationship Science
You
Mark Swanson
Executive Vice President, Head-Research & Strategic Development at Gel Med Sciences, Inc.
Education
Class of 1983

The University of Connecticut (UConn) is a public research university in Connecticut. Known as a Public Ivy,[3] UConn was founded in 1881 and is a Land Grant and Sea Grant college & member of the Space Grant Consortium. The institution serves more than 30,000 students on its six campuses, including more than 8,000 graduate students in multiple programs.[4] UConn's main campus is in Storrs, Connecticut. The university's president is Susan Herbst.[5] UConn is one of the founding institutions of the Hartford, Connecticut/Springfield, Massachusetts regional economic and cultural partnership alliance known as New England's Knowledge Corridor. UConn is a member of Universitas 21, a global network of 24 research-intensive universities, who work together to foster global citizenship and institutional innovation through research-inspired teaching and learning, student mobility, connecting students and staff, and promote advocacy for internationalisation.[6] UConn is accredited by the New England Association of Schools and Colleges.

Career History
Executive Vice President, Head-Research & Strategic Development
Current

Gel Med Sciences, Inc. engages in the development of animal and human healthcare products. It offers ovugel that utilizes the company's gel drug delivery system to improve the timing of artificial inseminations in pig herds. The company was founded by Joseph S Duffey in 1999 and is headquartered in Wayne, PA.

Vice President-Transgenic Sciences
Prior

DNX Transgenic Sciences, a subsidiary of PerkinElmer, Inc. (United States), is an American company that provides contract research services and transgenic animal technologies to the biomedical research community. The firm was acquired by Xenogen Corp., a subsidiary of PerkinElmer, Inc. (United States) since August 2006, from Nordion (Canada), Inc. on 13 Nov 00 for $35 million.

Senior Scientist
Prior

Sandoz, the generic pharmaceuticals division of Novartis, is a worldwide leader in generics. With a history of more than 120 years, Sandoz is a trusted leader with a reputation for exceptional quality. Our strategic and customer-focused approach to developing, producing and marketing high-quality affordable medicines following the loss of patent protection, has successfully made us one of the two largest and most respected generics companies worldwide.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Mark Swanson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Mark Swanson's profile does not indicate a business or promotional relationship of any kind between RelSci and Mark Swanson.